Stockscreener 앱 받기
2.83
3.08%
-0.09
시간 외 거래:
2.80
-0.03
-1.06%
AIM ImmunoTech Inc 주식(AIM)의 최신 뉴스
AIM ImmunoTech Closes $8 Million Public Offering - MSN
AIM ImmunoTech Announces Closing of $8.0 Million Public Offering - GlobeNewswire
AIM ImmunoTech's $8.0M Capital Raise: A Strategic Move to Fuel Ampligen's Clinical Progress and Investor Value? - AInvest
AIM ImmunoTech Secures $8M Funding: New Shares at $4.00 Plus 5-Year Warrants - Stock Titan
Biotech Alert: Searches spiking for these stocks today - TipRanks
AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering - GlobeNewswire
Evaluating AIM ImmunoTech's Capital Raise: A Strategic Crossroads for Investors - AInvest
AIM Shares Fall After Pricing of $8 Million Public Offering - MarketScreener
Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views - Benzinga
AIM ImmunoTech stock plunges after pricing $8 million public offering - Investing.com Australia
AIM ImmunoTech stock plunges after pricing $8 million public offering By Investing.com - Investing.com India
US Stocks Mixed; Procter & Gamble Posts Upbeat Earnings - Benzinga
AIM ImmunoTech prices $8 million public offering at $4.00 per share - Investing.com
AIM ImmunoTech Plunges 51.11% Amid Market Volatility - AInvest
AIM ImmunoTech prices 2M shares at $4.00 in public offering - TipRanks
AIM ImmunoTech Secures Fresh Capital: $8M Offering Includes Dual Warrant Structure at $4.00 - Stock Titan
AIM ImmunoTech Inc Plunges 38.33% Amid Trading Halt - AInvest
AIM ImmunoTech Stock Plunges 40.97% on Volatility - AInvest
Why Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
AIM ImmunoTech Reports Positive Mid-year Safety and - GlobeNewswire
AIM ImmunoTech Inc. Trading Resumes: Enhanced Tools and Expert Analysis Available for Investors - AInvest
Crude Oil Gains 2%; CEA Industries Shares Spike Higher - Benzinga
Why Is Micro-Cap AIM ImmunoTech Stock Surging? - Benzinga
AIM ImmunoTech's Ampligen: A Promising Catalyst for Shareholder Value in Pancreatic Cancer Therapy - AInvest
US Stocks Mixed; Enterprise Products Partners Posts Upbeat Earnings - Benzinga
AIM ImmunoTech Reports Positive Phase 2 Study Results - TipRanks
AIM ImmunoTech (AIM) reveals positive Phase 2 Ampligen pancreatic data | AIM SEC FilingForm 8-K - Stock Titan
Breakthrough in Pancreatic Cancer Treatment: New Phase 2 Data Shows 64% Survival Rate at 6 Months - Stock Titan
AIM ImmunoTech (NYSE:AIM) Stock Price Down 4.5% – Here’s What Happened - Defense World
Latest News - Asia Food Journal
AIM ImmunoTech granted U.S. patent for Ampligen - MSN
Omega Therapeutics (NASDAQ:OMGA) versus AIM ImmunoTech (NYSE:AIM) Head-To-Head Review - Defense World
AIM ImmunoTech Announces Recent Presentation on the - GlobeNewswire
AIM ImmunoTech (NYSE:AIM) Shares Gap Up – Here’s What Happened - Defense World
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements - The Manila Times
AIM ImmunoTech's Compliance Clock Ticks: Can Equity Challenges Be Overcome Before June 2026? - AInvest
AIM ImmunoTech resumes trading on NYSE American By Investing.com - Investing.com India
AIM ImmunoTech resumes trading on NYSE American - Investing.com
AIM ImmunoTech Resumes Trading on NYSE American - The Manila Times
AIM ImmunoTech Inc. Common Stock Resumes Trading on NYSE American - Nasdaq
Aim Immunotech CEO Thomas Equels acquires $823 in common stock By Investing.com - Investing.com India
Aim Immunotech CEO Thomas Equels acquires $823 in common stock - Investing.com
Aim Immunotech CEO Thomas Equels acquires shares worth $896 By Investing.com - Investing.com Nigeria
Aim Immunotech CEO Thomas Equels acquires shares worth $896 - Investing.com Australia
AIM ImmunoTech Announces NYSE American Removal of Trading Suspension - GlobeNewswire
AIM ImmunoTech Regains NYSE Compliance, Stock Reinstated - TipRanks
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen® - The Manila Times
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, ... - Bluefield Daily Telegraph
New Patent Grant Extends Ampligen Manufacturing Protection for 18 Years: Major Win for Cancer and COVID Drug - Stock Titan
0.93%
0.15%
자본화:
|
볼륨(24시간):